Suchergebnisse - "Ritonavir"

PubPharm (9.308)

131

PBPK Modeling of PAXLOVIDTM : Incorporating Rotamer Conversion Kinetics to Advanced Dissolution and Absorption Model

enthalten in: Journal of pharmaceutical sciences | 2024

von Jaini, R. | Lin, J. | Di, L. | +1

132

Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults

enthalten in: British journal of clinical pharmacology | 2024

von Zhang, Y. | Joshi, S. | Yazdani, P. | +6

133

Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection

enthalten in: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy | 2024

von Ito, W. | Fukumori, T. | Asaoka, N. | +13

134

A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir

enthalten in: Clinical pharmacokinetics | 2024

von Gerhart, J. | Cox, D. | Singh, R. | +6

135

Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19 : a retrospective observational study

enthalten in: BMC infectious diseases | 2024

von Zhou, Z. | Zheng, H. | Xiao, G. | +3

136

Nirmatrelvir-Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak : Real-World Evidence from Beijing

enthalten in: Infection and drug resistance | 2024

von Zhang, Y. | Wang, X. | Huang, C. | +9

137

Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study

enthalten in: BMC infectious diseases | 2024

von Zhou, Z. | Zheng, H. | Xiao, G. | +3

138

Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients

enthalten in: BMC infectious diseases | 2024

von Su, P. | Yang, C. | Wang, X.

139

Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients

enthalten in: BMC infectious diseases | 2024

von Su, P. | Yang, C. | Wang, X.

140

Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania

enthalten in: PloS one | 2024

von Jiwa, N. | Ketang'enyi, E. | Nganyanyuka, K. | +12